Skip to content

Pelvic floor therapies after surgery for gynaecological cancer: a telehealth intervention trial

The feasibility of pelvic floor therapies to treat pelvic floor dysfunction in women following surgery for gynaecological cancer: a telehealth intervention trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12621000880842
Enrollment
36
Registered
2021-07-08
Start date
2022-01-19
Completion date
2022-05-28
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to determine if a physiotherapist supervised pelvic floor muscle training intervention delivered online is feasible for participants with incontinence who have previously had a surgery for a gynaecological cancer. Who is it for? You may be eligible for this study if you are an adult female who has previously had a surgery for a gynaecological cancer. Study details All participants who choose to enrol in this study will receive a femfit® device that provides live data on the person's ability to correctly contract their pelvic floor muscles. All participants will be offered 7 sessions with the research physiotherapist via videoconference (e.g. Zoom platform or similar) over a 12 week period. Each session will be 30 minutes. Using the femfit® device, the research physiotherapist will then teach the pelvic floor muscle training program. As a home exercise program, the participant will complete the pelvic floor muscle training program using the femfit® app and record their progress on an exercise diary within the femfit® app. Participants who require conservative therapy will also receive additional education regarding incontinence alongside the intervention. All participants complete questionnaires at the end of 12 weeks, and 3 months after the intervention finishes, to assess their pelvic floor symptoms. Three months after the intervention, all participants will complete a short telephone survey, and may be invited to participate in in-depth interviews, about whether they found the intervention to be acceptable. It is hoped this research will demonstrate that a physiotherapy program delivered via telehealth is a feasible method of providing pelvic floor muscle rehabilitation and improving quality of life for those who have received surgery for a gynaecological cancer.

Interventions

Pelvic floor muscle training (PFMT) + home exercise program + non-exercise components Pelvic floor muscle training (PFMT) intervention: o 'What' The intervention: 7 x 30 minute telehealth sessions over 12 weeks (e.g. at 0, 2, 4, 6, 8, 10 & 12 weeks). o 'Who' The provider: Physiotherapist with postgraduate qualification in pelvic floor physiotherapy o 'How' Group or individual: Individual telehealth-delivered instruction in PFMT, customised to each participant’s starting level of ability to do PF

Pelvic floor muscle training (PFMT) + home exercise program + non-exercise components Pelvic floor muscle training (PFMT) intervention: o 'What' The intervention: 7 x 30 minute telehealth sessions over 12 weeks (e.g. at 0, 2, 4, 6, 8, 10 & 12 weeks). o 'Who' The provider: Physiotherapist with postgraduate qualification in pelvic floor physiotherapy o 'How' Group or individual: Individual telehealth-delivered instruction in PFMT, customised to each participant’s starting level of ability to do PFMT Supervision: Individually-supervised remotely via telehealth Each woman will also receive a Femfit® intravaginal pressure biofeedback device to help teach the correct contraction technique, to monitor pelvic floor muscle (PFM) strength gains during telehealth consultations and home practice, and to aid adherence to PFMT home exercise program via the Femfit® app which the participant will download to their phone. Adherence to exercise measures: Exercise diaries Motivation strategies: Behaviour change techniques (biofeedback, behaviour goal setting, action planning including implementation intentions, instruction on how to perform behaviour (PFM exercise), outcome goal setting, review of behaviour goals, problem solving, verbal persuasion to boost self-efficacy, self- monitoring, association with prompts or cues) Progression - decision when to progress: Every 4 weeks Detailed description of exercise session: Using real-time feedback from the Femfit biofeedback device and app, the Femfit strength building protocol will be used, as follows: 3 sets of 6 repetitions of a pelvic floor muscle contraction of 6 seconds instructed to be held at maximal voluntary contraction strength, with 6 seconds rest in between, then 3 sets of 6 repetitions of a rapid pelvic floor contraction (1 second hold, 1 second rest) instructed to be completed at maximal voluntary contraction strength, then 3 repetitions of a pelvic floor muscle endurance contractions instructed to be held at 50%-100% of maximal voluntary effort for 18 seconds, followed by 18 seconds rest, then 3 sets of coordination contractions with a rapid pelvic floor contraction and cough, instructed to be performed at the same time, 3 times in a row. Progression - type: Duration of muscle hold and number of repetitions; increasing anti-gravity positions Adherence to intervention measure: clinician record of participant attendance or non-attendance to intervention sessions and of the components of therapy completed within each session. + Home exercise program component: Exercises detailed in home exercise handout specifying position, time, dosage, effort, which can be done with and without the Femfit® intravaginal pressure biofeedback device. The exercise is a daily local muscle exercise of the pelvic floor muscles as per the 12-week strength building programme included in the Femfit mobile device app and is the same as the supervised exercise session that will be done with the physiotherapist via telehealth. Exercise sessions will take 8-18 minutes. Intensity of each contraction will be determined by self-perceived percentage of maximal voluntary contraction strength, with each contraction instructed to be done at 50-100% of maximal voluntary contraction strength. This will be done over the same 12 weeks as the weekly telehealth sessions. Adherence will be monitored by the exercise diary included in the Femfit app. +/- Non-exercise component: Participants who present with symptoms of PFD which require conservative therapies other than PFM exercise, as assessed by the clinician providing the intervention, will be provided with these education-based therapies at their first post-operative physiotherapy session, and continued alongside PFM exercise as required: For urinary urgency and frequency or urge urinary incontinence: bladder training including urinary urge suppression techniques, education on fluid intake modification including caffeine reduction if relevant, and education in good bladder and bowel habits. For faecal incontinence: bowel routine training, education on dietary fibre including psyllium supplementation, education on faecal urgency suppression techniques and education about defecation dynamics and toileting posture. These components will be provided with an additional 5-15 minutes at each telehealth session to address each component. Any time spent addressing these components will be recorded by the clinician providing the intervention.

Sponsors

University of Melbourne
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Women who have had surgery for primary gynaecological treatment for uterine, endometrial, cervical or ovarian cancer, based on oncology assessment, or a histologically confirmed uterine, endometrial, cervical or ovarian tumour, International Federation of Gynecology and Obstetrics (FIGO) cancer staging system classification stages I-III (if known); have any type of urinary and/or faecal incontinence, have an Eastern Cooperative Oncology Group performance status of between 0-2 (with a score of 0 being fully active to and a score of 2 being resting in bed less than 50% of the day); have the capability and access to use a telecommunication platform in their own home; have sufficient English language skills to participate; and are at least 18 years of age.

Exclusion criteria

Women with a FIGO cancer staging system classification stage IV, who are pregnant, up to 12 months postnatal or who are breastfeeding, have neurological disorders or severe physical/psychiatric impairments, or who have, within the last 2 years, received physiotherapist-supervised PFMT or pelvic surgery for incontinence or pelvic organ prolapse will be excluded.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 8, 2026